Literature DB >> 26318161

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Nazzareno Galiè1, Marc Humbert2, Jean-Luc Vachiery3, Simon Gibbs4, Irene Lang4, Adam Torbicki4, Gérald Simonneau5, Andrew Peacock5, Anton Vonk Noordegraaf5, Maurice Beghetti6, Ardeschir Ghofrani5, Miguel Angel Gomez Sanchez4, Georg Hansmann6, Walter Klepetko3, Patrizio Lancellotti4, Marco Matucci7, Theresa McDonagh4, Luc A Pierard4, Pedro T Trindade4, Maurizio Zompatori8, Marius Hoeper5.   

Abstract

Guidelines summarize and evaluate all available evidence on a particular issue at the time of the writing process, with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well as the risk-benefit ratio of particular diagnostic or therapeutic means. Guidelines and recommendations should help health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate. Published on behalf of the European Society of Cardiology and European Respiratory Society. All rights reserved.
© 2015 European Society of Cardiology & European Respiratory Society.

Entities:  

Mesh:

Year:  2015        PMID: 26318161     DOI: 10.1183/13993003.01032-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  658 in total

1.  Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.

Authors:  Marius M Hoeper; Tilmann Kramer; Zixuan Pan; Christina A Eichstaedt; Jens Spiesshoefer; Nicola Benjamin; Karen M Olsson; Katrin Meyer; Carmine Dario Vizza; Anton Vonk-Noordegraaf; Oliver Distler; Christian Opitz; J Simon R Gibbs; Marion Delcroix; H Ardeschir Ghofrani; Doerte Huscher; David Pittrow; Stephan Rosenkranz; Ekkehard Grünig
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

2.  Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.

Authors:  Athénaïs Boucly; Jason Weatherald; Laurent Savale; Xavier Jaïs; Vincent Cottin; Grégoire Prevot; François Picard; Pascal de Groote; Mitja Jevnikar; Emmanuel Bergot; Ari Chaouat; Céline Chabanne; Arnaud Bourdin; Florence Parent; David Montani; Gérald Simonneau; Marc Humbert; Olivier Sitbon
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

3.  Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome.

Authors:  Christopher J Rhodes; Pablo Otero-Núñez; John Wharton; Emilia M Swietlik; Sokratis Kariotis; Lars Harbaum; Mark J Dunning; Jason M Elinoff; Niamh Errington; A A Roger Thompson; James Iremonger; J Gerry Coghlan; Paul A Corris; Luke S Howard; David G Kiely; Colin Church; Joanna Pepke-Zaba; Mark Toshner; Stephen J Wort; Ankit A Desai; Marc Humbert; William C Nichols; Laura Southgate; David-Alexandre Trégouët; Richard C Trembath; Inga Prokopenko; Stefan Gräf; Nicholas W Morrell; Dennis Wang; Allan Lawrie; Martin R Wilkins
Journal:  Am J Respir Crit Care Med       Date:  2020-08-15       Impact factor: 21.405

4.  Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Yu Taniguchi; Philippe Brenot; Xavier Jais; Carlos Garcia; Jason Weatherald; Olivier Planche; Elie Fadel; Marc Humbert; Gérald Simonneau
Journal:  Chest       Date:  2018-05-03       Impact factor: 9.410

5.  Red blood cell distribution width as a potential predictor of survival of pulmonary arterial hypertension associated with primary Sjogren's syndrome: a retrospective cohort study.

Authors:  Min Hui; Jiuliang Zhao; Zhuang Tian; Jieying Wang; Junyan Qian; Xiaoxi Yang; Qian Wang; Mengtao Li; Yan Zhao; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2018-09-14       Impact factor: 2.980

6.  Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry.

Authors:  Francisco J García-Hernández; María J Castillo-Palma; Carles Tolosa-Vilella; Alfredo Guillén-Del Castillo; Manuel Rubio-Rivas; Mayka Freire; José A Vargas-Hitos; José A Todolí-Parra; Mónica Rodríguez-Carballeira; Gerard Espinosa-Garriga; Dolores Colunga-Argüelles; Norberto Ortego-Centeno; Luis Trapiella-Martínez; María M Rodero-Roldán; Xavier Pla-Salas; Isabel Perales-Fraile; Isaac Pons-Martín Del Campo; Antonio J Chamorro; Rafael A Fernández-de la Puebla Giménez; Ana B Madroñero-Vuelta; Manuel Ruíz-Muñoz; Vicent Fonollosa-Pla; Carmen P Simeón-Aznar
Journal:  Clin Rheumatol       Date:  2018-12-07       Impact factor: 2.980

7.  Plasma MMP2/TIMP4 Ratio at Follow-up Assessment Predicts Disease Progression of Idiopathic Pulmonary Arterial Hypertension.

Authors:  Veronika Wetzl; Svenja Lena Tiede; Lothar Faerber; Norbert Weissmann; Ralph Theo Schermuly; Hossein Ardeschir Ghofrani; Henning Gall
Journal:  Lung       Date:  2017-05-17       Impact factor: 2.584

8.  NLRC3: A Novel Noninvasive Biomarker for Pulmonary Hypertension Diagnosis.

Authors:  Li-Huang Zha; Jun Zhou; Tang-Zhiming Li; Hui Luo; Jing-Ni He; Lin Zhao; Zai-Xin Yu
Journal:  Aging Dis       Date:  2018-10-01       Impact factor: 6.745

9.  Ante-mortem diagnosis of pulmonary tumour thrombotic microangiopathy in a patient with unrecognised extramammary Paget's disease.

Authors:  Aya Banno; Keijiro Chiba; Hiroko Kasai; Keiichi Nagami
Journal:  BMJ Case Rep       Date:  2016-08-26

Review 10.  Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.

Authors:  Shuyan Gu; Huimei Hu; Hengjin Dong
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.